GLMD: חובות מצטברים של החברה Galmed Pharma

Drug development at Galmed Pharmaceuticals (GLMD) requires massive research investments, leading to a proportional increase in laboratory costs. Galmed Pharmaceuticals (GLMD) strictly adheres to ESG standards by modernizing wastewater treatment and energy efficiency. This chart demonstrates a separate debt, which currently stands at 0.00. The business relies on bioinformatics IT solutions, automating the creation of molecules to combat liver pathologies without manual labor.

This indicator aggregates the total volume of all the issuer's credit obligations, allowing for an assessment of default risk and expansion potential through an analysis of the borrowing structure. Amid the formation of new strategies to combat liver pathologies, the amount of funds raised demonstrates the financial cushion of Galmed Pharmaceuticals (GLMD) to implement its updated clinical pipeline given the current market undervaluation of assets.